SaNOtize Research & Development Corp.: Newly Published Phase

Phase 3 trial demonstrated a reduction in SARS-CoV-2 viral load in high-risk COVID-19 patients by 94% and 99% within 24 and 48 hours of treatment, respectively Median time to a negative PCR

Related Keywords

Canada , Thailand , India , Hong Kong , United Kingdom , Israel , Singapore , Nepal , Vancouver , British Columbia , Indonesia , Bahrain , Canadian , Chris Miller , Kostenloser Wertpapierhandel , Sean Gjos , Gilly Regev , Sanotize Co , Thelancet Regional Health Southeast Asia , Linkedin , Twitter , Sanotize Research Development Corp , European Union , India Central Drugs Standard Control Organization , Glenmark Pharmaceuticals Limited , Business Development , Research Development Corp , Progression Scale , Chief Scientific Officer , Central Drugs Standard Control Organization , Research Development , Nitric Oxide Releasing Solution , Media Contact , Sanotize , Research , Development , Orp , Ewly , Published , Hase , Study , People , Covid , Shows , Mitric , Xide , Nasal , Spray , Educed , Viral , Road , Ithin , Ways ,